MedPath

Early evaluation for chemotherapy response of lung cancer using a new PET/CT tracer of DNA synthesis.

Not Applicable
Conditions
on-small cell lung caner
Registration Number
JPRN-UMIN000012322
Lead Sponsor
ational Center for Global Health and Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

Those who have not signed the informed consent form. Those who have symptomatic brain metastasis, or active double cancer, or active infectious disease, or spinal metastasis that required immediate surgery or radiotherapy, or uncontrollable hypertension, or ischemic heart disease, or uncontrollable diabetes. Those who have been decided not appropriate by the physician.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
If the tumor uptake reduction of 4DST after chemotherapy is larger and earlier than that of FDG or not.
Secondary Outcome Measures
NameTimeMethod
The correlation of the tumor uptake reductions of 4DST or FDG after chemotherapy and the tumor volume reduction, and the progression free survival.
© Copyright 2025. All Rights Reserved by MedPath